(Q40703922)

22 September 2017

title

Contribution of apoptosis in the cytotoxicity of the oxaliplatin-irinotecan combination in the HT29 human colon adenocarcinoma cell line (English)

1 reference

22 September 2017

1 reference

Stéphanie Arnould

1

1 reference

22 September 2017

Sylvie Guichard

2

1 reference

22 September 2017

Isabelle Hennebelle

3

1 reference

22 September 2017

Georges Cassar

4

1 reference

22 September 2017

Roland Bugat

5

1 reference

22 September 2017

Pierre Canal

6

1 reference

22 September 2017

language of work or name

English

0 references

publication date

1 October 2002

1 reference

22 September 2017

published in

Biochemical Pharmacology

1 reference

22 September 2017

volume

64

1 reference

22 September 2017

issue

8

1 reference

22 September 2017

page(s)

1215-1226

1 reference

Different fates of camptothecin-induced replication fork-associated double-strand DNA breaks in mammalian cells

22 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901291-1

Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901291-1

Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901291-1

Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901291-1

Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901291-1

Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901291-1

Phase I-II study of irinotecan in combination with mitomycin C in patients with advanced gastrointestinal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901291-1

In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901291-1

Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901291-1

Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901291-1

Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901291-1

A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901291-1

Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901291-1

Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901291-1

Programmed cell death in animal development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901291-1

Apoptosis signaling by death receptors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901291-1

New colorimetric cytotoxicity assay for anticancer-drug screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901291-1

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901291-1

A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901291-1

Measurement of cell-cycle phase-specific cell death using Hoechst 33342 and propidium iodide: preservation by ethanol fixation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901291-1

Time-schedule dependency of the inhibiting activity of various anticancer drugs in the clonogenic assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901291-1

Combination of oxaliplatin and irinotecan on human colon cancer cell lines: activity in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901291-1

Effects of CPT-11 in combination with other anti-cancer agents in culture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901291-1

Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901291-1

Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901291-1

Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901291-1

Replication-mediated DNA damage by camptothecin induces phosphorylation of RPA by DNA-dependent protein kinase and dissociates RPA:DNA-PK complexes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901291-1

Efficient translesion replication past oxaliplatin and cisplatin GpG adducts by human DNA polymerase eta.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901291-1

The Efficiency and Fidelity of Translesion Synthesis past Cisplatin and Oxaliplatin GpG Adducts by Human DNA Polymerase β

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901291-1

p53 mutations in colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901291-1

Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901291-1

Intracellular adenosine triphosphate (ATP) concentration: a switch in the decision between apoptosis and necrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901291-1

Cellular pharmacology of the combination of oxaliplatin with topotecan in the IGROV-1 human ovarian cancer cell line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901291-1

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0006-2952(02)01291-1

1 reference

22 September 2017

1 reference